Cardiff was downgraded by TD Cowen and H.C. Wainwright after Nerviano Medical Sciences terminated the onvansertib license agreement. Company calls termination invalid and is fighting in court.
Wells Fargo upgraded Tandem Diabetes, raising price target to $27 on strong growth, better pharmacy model, and positive outlook.
Truist is bullish on ArriVent, rating Buy and seeing firmonertinib as a strong lung cancer drug with up to $1.1B peak sales.
Cantor is bullish on Sensei Biotherapeutics for its cancer drug PIKTOR, with Phase 2 data soon as a key stock catalyst.
Editas’ gene therapy EDIT-401 cut bad cholesterol ~90% in animals; analysts bullish; human trials expected in 2026.
Hemab targets rare bleeding diseases with new treatments, strong cash, and big growth potential, with analysts seeing ~50% upside.
